Response-guided neoadjuvant sacituzumab govitecan for localized TNBC
Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). In this podcast, Annals of Oncology Edi